



The University of Georgia

## Funded Clinical Trials for Cats with Cancer

The oncology program at the University of Georgia's College of Veterinary Medicine would like to inform you about funded clinical trials available for **cats with cancer**. If you are a Referring Veterinarian and are interested in a consult, or if you are interested in referring a client for one of these trials, please call Dr. Corey Saba, Dr. Jessica Lawrence, or Dr. Nicole Northrup at 1-(800)-861-7456, locally at (706)-542-5362.

### **Phase I Clinical Trial of Vinorelbine in Tumor-Bearing Cats**

Vinorelbine is a semisynthetic vinca alkaloid belonging to the same class as vincristine and vinblastine. This drug has been used in people and dogs with various cancers, and although well-tolerated, neutropenia has been the dose-limiting toxicity in both species. Anecdotally, it has been used in cats at low dosages with no toxicity. However, to date, no clinical trials have been conducted.

The objectives of this study are to determine the dose-limiting toxicity and maximum tolerated dosage, to establish a safe starting dosage, and to elucidate treatment-related side effects of vinorelbine in tumor-bearing cats.

#### **Eligibility Criteria:**

1. Cats with any cytologically and/or histologically confirmed cancer are eligible.
2. They may have measurable or microscopic disease to participate.
3. They may have had prior surgery, radiotherapy, and/or chemotherapy. However, there must be at least a four week lapse between any of these treatments and entry into the trial.
4. Cats may not receive non-steroidal anti-inflammatory drugs (NSAIDs) or steroids while in the study and must undergo a 72 hour washout period if on NSAIDs or steroids prior to study initiation.
5. They must have normal organ and bone marrow function and have an expected survival of at least 4 weeks.
6. Owners must sign a consent form.

Preliminary staging tests for all cats will include initial consultation and physical examination, complete blood count (CBC), serum biochemical profile, and urinalysis. Once accepted into the study, the intent will be to administer escalating dosages of vinorelbine to each cat at weekly intervals. A CBC will be rechecked prior to each treatment. The costs of the initial tests, four vinorelbine treatments, and complete blood counts will be paid by the study if the cat qualifies. Assuming the cat tolerates the first four treatments well, treatments may be continued, off study, at the owner's expense. Complications of chemotherapy will **NOT** be covered by the study.